Browsing by Author "Marinho-Dias, Joana"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Impact of cervicovaginal microbiome on the risk of cervical abnormalities developmentPublication . Rosário, Andreia; Sousa, Ana Isabel; Varandas, Tatiana; Marinho-Dias, Joana; Medeiros, Rui; Martins, Maria Gabriela; Monteiro, Paula; Sousa, HugoThe vaginal microbiome has emerged as potentially influencing the natural history of Human Papillomavirus (HPV) infections and their clinical impact. We aimed to characterize the vaginal microbiome in samples from 807 high-risk HPVs (Hr-HPV) positive women with a mean age of 41.45 +/- 10.79 years who participated in the Regional Cervical Cancer Screening Program from the Northern Region of Portugal. Microbiome analysis was performed with commercial kits for the detection of 21 microorganisms. The most frequent microorganisms were Ureaplasma parvum (52.5%), Gardnerella vaginalis (GV) (34.5%), Atopobium vaginae (AV) (32.6%), Lacto (30.7%), and Mycoplasma hominis (MH) (23.5%). The distribution according to age reveals that MH, Mega1, GV, BVab2, AV, and Mob were more prevalent in women older than 41 years of age (p < 0.050), while Lacto is significantly decreased in this group (23.5% vs. 39.4%, p < 0.001; RR = 0.47). The risk analysis showed that Hr-HPV-16/-18 and Hr-HPV-9val genotypes are associated with an increased risk of developing cervical abnormalities, while Lacto (p < 0.001; odd ratio [OR] = 0.33), GV (p = 0.0111; OR = 0.41), AV (p = 0.033; OR = 0.53) and Mob (p = 0.022; OR = 0.29) are associated with protection. Similar results were found for the risk of development atypical squamous cells cannot exclude HSIL/high-grade squamous intraepithelial lesion. Overall, the multivariate analysis confirmed that lactobacillus and bacteria associated with bacterial vaginosis (GV, AV, and Mob) are associated with protection against the development of cervical abnormalities. This study provides important data to be included in the future management of risk stratification for Hr-HPV-positive women.
- Impact of high‐risk human papilloma virus genotyping in cervical disease in the Northern region of Portugal: real‐world data from regional cervical cancer screening programPublication . Rosário, Andreia; Sousa, Ana Saraiva; Marinho-Dias, Joana; Medeiros, Rui; Lobo, Cláudia; Leça, Luís; Coimbra, Nuno; Tavares, Fernando; Baldaque, Inês; Martins, Maria Gabriela; Monteiro, Paula; Henrique, RuiCervical cancer prevention is based on primary prevention with vaccines againstHuman Papillomavirus (HPV) and secondary prevention by screening with High‐Risk‐HPV (Hr‐HPV) detection. Since 2017, cervical cancer screening in women aged25−60 years has been performed in Portugal using Hr‐HPV detection, followed bycytology in Hr‐HPV‐positive cases. Herein we report the prevalence of Hr‐HPVgenotypes and cytological abnormalities among 462 401 women (mean age:43.73 ± 10.79; median age: 45; range: 24−66 years) that participated in the RegionalCervical Cancer Screening Program of the Northern Region of Portugal, performedbetween August 2016 and December 2021. Overall, we describe a prevalence rateof 12.50% for Hr‐HPV varying from 20.76% at age 25% to 8.32% at age 64. The fivemost common Hr‐HPV genotypes identified were HPV‐68 (16.09%), HPV‐31(15.30%), HPV‐51 (12.96%), HPV‐16 (11.06%), and HPV‐39 (11.01%). Theprevalence of Hr‐HPV included in the nonavalent vaccine (HPV‐9valent) was55.00% ranging from 47.78% to 59.18% across different age groups.